Sepideh Dashti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8389958/publications.pdf

Version: 2024-02-01

840776 940533 24 322 11 16 citations h-index g-index papers 24 24 24 393 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	HOX transcript antisense RNA: An oncogenic IncRNA in diverse malignancies. Experimental and Molecular Pathology, 2021, 118, 104578.	2.1	9
2	Deleted in lymphocytic leukemia 2 (DLEU2): An IncRNA with dissimilar roles in different cancers. Biomedicine and Pharmacotherapy, 2021, 133, 111093.	5.6	11
3	BCYRN1: An oncogenic IncRNA in diverse cancers. Pathology Research and Practice, 2021, 220, 153385.	2.3	12
4	A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies. Biomedicine and Pharmacotherapy, 2021, 137, 111366.	5.6	19
5	X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis. Frontiers in Cell and Developmental Biology, 2021, 9, 690522.	3.7	11
6	Cellular immune responses against cancer-germline genes in cancers. Human Antibodies, 2020, 28, 57-64.	1.5	1
7	Expression analysis of NF-κB interacting long noncoding RNAs in breast cancer. Experimental and Molecular Pathology, 2020, 112, 104359.	2.1	9
8	TINCR: An IncRNA with dual functions in the carcinogenesis process. Non-coding RNA Research, 2020, 5, 109-115.	4.6	29
9	An in-silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer. Scientific Reports, 2020, 10, 18770.	3.3	18
10	In silico identification of MAPK14-related IncRNAs and assessment of their expression in breast cancer samples. Scientific Reports, 2020, 10, 8316.	3.3	23
11	The role of long non-coding RNA CASC2 in the carcinogenesis process. Biomedicine and Pharmacotherapy, 2020, 127, 110202.	5.6	17
12	Expression profile of lncRNAs and miRNAs in esophageal cancer: Implications in diagnosis, prognosis, and therapeutic response. Journal of Cellular Physiology, 2020, 235, 9269-9290.	4.1	17
13	Expression analysis of growth arrest specific 8 and its anti-sense in breast cancer tissues. Experimental and Molecular Pathology, 2020, 114, 104414.	2.1	2
14	PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target. Experimental and Molecular Pathology, 2020, 114, 104429.	2.1	12
15	Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer. Experimental and Molecular Pathology, 2020, 114, 104415.	2.1	8
16	Assessment of anti-cancer effects of koenimbine on colon cancer cells. Human Antibodies, 2020, 28, 185-190.	1.5	3
17	The HOTTIP (HOXA transcript at the distal tip) IncRNA: Review of oncogenic roles in human. Biomedicine and Pharmacotherapy, 2020, 127, 110158.	5.6	42
18	Expression analysis of vimentin and the related lncRNA network in breast cancer. Experimental and Molecular Pathology, 2020, 115, 104439.	2.1	25

SEPIDEH DASHTI

#	Article	IF	CITATIONS
19	Assessment of the expression pattern of mTORâ€associated lncRNAs and their genomic variants in the patients with breast cancer. Journal of Cellular Physiology, 2019, 234, 22044-22056.	4.1	18
20	Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies. BMC Medical Genetics, 2019, 20, 79.	2.1	10
21	Humoral immune responses against cancer-testis antigens in human malignancies. Human Antibodies, 2019, 27, 237-240.	1.5	5
22	Cancer-testis antigens: An update on their roles in cancer immunotherapy. Human Antibodies, 2019, 27, 171-183.	1.5	3
23	Expression of brain-derived neurotrophic factor (BDNF) and its naturally occurring antisense in breast cancer samples. Meta Gene, 2019, 19, 69-73.	0.6	7
24	Mutation analysis of SLC3A1 and SLC7A9 genes in patients with cystinuria. Urolithiasis, 2015, 43, 447-453.	2.0	11